Highlighted PresentationsPharmacologyAntiplatelet

SOLACI-SBHCI 2023 | Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel – Dr. Roxana Mehran

solaci
solaci
1100
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Roxana Mehran, entitled “Patient-centered Selection Anti-platelet Treatment for ACS-PCI Patients: Real World Evidence of Prasugrel”.

Roxana-Mehran-patient-centered-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SBHCI 2023 | High bleeding and ischemic dilemma: how to evaluate and predict? – Dr. Roxana Mehran
Next article
SOLACI-SBHCI 2023 | Tips and Tricks with Renal Denervation – Dr. María Sanalí Paiva
solaci
solaci

More articles by this author

Shortened DAPT Regimens According to the PRECISE-HBR Score

Dr. Omar Tupayachi - 0
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Dr. Juan Manuel Pérez - 0
Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

Dr. Andrés Rodríguez - 0
In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

Dr. Andrés Rodríguez - 0
This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

Shortened DAPT Regimens According to the PRECISE-HBR Score

The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Shortened DAPT Regimens According to the PRECISE-HBR Score

Dr. Omar Tupayachi - 0
The optimal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention depends on balancing the prevention of ischemic events against the risk of...

SAFE-PROTECT at 12 Months: AnchorMan vs. Watchman for Left Atrial Appendage Closure

Dr. Andrés Rodríguez - 0
Percutaneous left atrial appendage (LAA) closure is an alternative therapeutic strategy for reducing the risk of stroke in patients with atrial fibrillation (AF). Randomized...

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

Dr. Andrés Rodríguez - 0
According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...